Bifidobacterium adolescentis AF91-08b2A and application thereof in relieving ulcerative colitis

Through the combination of Bifidobacterium adolescentis AF91-08b2A strain and vitamin C, the side effects and poor efficacy in the treatment of ulcerative colitis were solved, and the mouse model of ulcerative colitis was significantly improved, providing a safer More effective treatment options.

CN119081926APending Publication Date: 2024-12-06FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV +1
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411183086.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing treatment methods for ulcerative colitis have problems such as side effects, high cost and insignificant efficacy, especially the treatment methods for ulcerative colitis are difficult to provide safer and more effective solutions.

Method used

Bifidobacterium adolescentis AF91-08b2A strain was used as a new treatment plan. This strain significantly improved the disease activity index of DSS-induced UC mice, controlled weight loss and colon shortening, and improved intestinal barrier function and reduced inflammatory response, combined with vitamin C and other nutrients to prepare pharmaceutical or food compositions to enhance efficacy.

Benefits of technology

Bifidobacterium adolescentis AF91-08b2A significantly improves mouse models of ulcerative colitis, reduces disease activity index, improves intestinal barrier function, reduces inflammatory response, and has better therapeutic effects and safety than traditional drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119081926A_ABST
    Figure CN119081926A_ABST
Patent Text Reader

Abstract

The invention is applicable to the technical field of microorganisms, and provides bifidobacterium adolescentis AF91-08b2A with the preservation number of GDMCC (China General Microbiological Culture Collection Center) NO: 64745. The invention further provides a preparation method of the bifidobacterium adolescentis AF91-08b2A. The bifidobacterium adolescentis AF91-08b2A disclosed by the invention can be used for remarkably improving the disease activity index (DAI) of a DSS induced UC mouse, controlling the weight loss and the colon shortening of the UC mouse, improving the intestinal barrier function and reducing the inflammatory response.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of microbial technology improvement, and in particular relates to Bifidobacterium adolescentis AF91-08b2A and its application in preventing and alleviating ulcerative colitis. More specifically, the present invention relates to a pharmaceutical composition, a food composition, and the use of Bifidobacterium adolescentis in preparing medicines, foods or health products. Background Art

[0002] Inflammatory bowel disease (IBD) is a class of chronic inflammatory diseases that affect the gastrointestinal tract, including Crohn's disease (CD) and ulcerative colitis (UC). The global incidence of IBD is on the rise, especially in industrialized countries. The exact cause of IBD has not yet been fully elucidated, but it is generally believed to be caused by a complex interaction between genetics, the immune system, environmental factors, and the intestinal microbiota.

[0003] In recent years, with the development of metagenomics and microbiome, people have gradually realized the close connection between intestinal microbiota and IBD. Imbalance of intestinal microbiota, also known as intestinal dysbiosis, is believed to play a key role in the pathogenesis of IBD. Intestinal dysbiosis involves the reduction of beneficial microorganisms and the overgrowth of pathogenic bacteria, which may lead to impaired intestinal barrier function and chronic inflammation.

[0004] A variety of drugs and treatments have been developed to treat IBD, including salicylates, glucocorticoids, immunosuppressants, and biologics. However, these treatments are often accompanied by side effects or high costs, and not all patients can achieve satisfactory results. Therefore, finding new treatment strategies to improve the quality of life and treatment outcomes of IBD patients is an important research area.

[0005] In recent years, probiotics have received widespread attention as a potential therapeutic approach. Probiotics are live bacteria that can provide health benefits to the host. In particular, certain strains of Bifidobacterium have been shown to have positive effects on intestinal health, including improving intestinal barrier function, regulating immune responses, and inhibiting the growth of pathogens. Bifidobacterium adolescentis is a species of Bifidobacterium that is common in the intestines of healthy adults and has been studied for the treatment of constipation and irritable bowel syndrome (IBS).

[0006] At present, the clinical treatment of ulcerative colitis (UC) mainly includes: Drug treatment Salicylic acid drugs: This type of drug relieves inflammatory responses by inhibiting prostaglandin synthesis and scavenging oxygen free radicals. Commonly used salicylic acid drugs in clinical practice include sulfasalazine (SASP) and mesalazine, which are mainly used to treat mild to moderate UC patients.

[0007] Glucocorticoids: For patients with severe or fulminant UC, glucocorticoids such as betamethasone (Budesonide) are the first choice treatment, which can effectively control inflammation.

[0008] Immunosuppressants: Cyclosporine and other immunosuppressants inhibit UC by inhibiting the production of IL-2 by T cells, affecting the progression of the immune response.

[0009] Biological agents: In recent years, biological agents have become an important means of treating UC, especially for patients who are ineffective with traditional treatments. Biological agents mainly target specific immune cells or cytokines, such as anti-tumor necrosis factor-α (TNF-α) drugs infliximab and adalimumab. These drugs can specifically inhibit key mediators in the inflammatory process, thereby alleviating symptoms and promoting mucosal healing.

[0010] Surgery When medical treatment is ineffective or serious complications occur, surgical treatment, such as colectomy, may be necessary.

[0011] Although existing treatments can alleviate the symptoms of UC to some extent, they have some disadvantages and limitations: Salicylate drugs may cause side effects such as gastrointestinal reactions, headaches, allergic reactions, rashes, hepatotoxicity, leukopenia and anemia. The use of glucocorticoids may cause side effects such as metabolic disorders and water retention, and due to their side effects, they are usually only used as short-term emergency treatments and are not suitable for long-term use. Immunosuppressant therapy is drug-dependent, has a long treatment cycle, may cause nephrotoxicity and increase the risk of secondary infection, and is usually used as an adjuvant treatment. Although biological agents have significant efficacy, they may cause side effects such as increased risk of infection and allergic reactions, and their high cost limits their widespread application. Therefore, existing treatments need to be further improved to provide safer, more effective, and less side-effect treatment options. Summary of the invention

[0012] This study focused on the Bifidobacterium adolescentis AF91-08b2A strain and explored its potential application in the prevention and treatment of IBD. By analyzing the genomic characteristics of this strain, safety assessment, and therapeutic effects in animal models, it aims to provide new insights and strategies for the treatment of IBD.

[0013] The technical problem to be solved by the present invention is to provide a Bifidobacterium adolescentis AF91-08b2A and its application in relieving ulcerative colitis.

[0014] That is, the present invention provides a new application of Bifidobacterium adolescentis AF91-08b2A for treating colitis. It has been proven that the strain can significantly improve the disease activity index (DAI) of DSS (dextran sulfate sodium)-induced UC mice, control the weight loss and colon shortening of UC mice, improve the intestinal barrier function and reduce the inflammatory response, and has better therapeutic effects than existing therapeutic drugs.

[0015] In order to solve the above-mentioned technical problems, the present invention is implemented as follows: a Bifidobacterium adolescentis AF91-08b2A was deposited in Guangdong Provincial Microbiological Culture Collection Center on June 13, 2024, and its preservation number is GDMCC NO: 64745.

[0016] Another object of the present invention is to provide a pharmaceutical composition for treating and / or preventing and / or alleviating inflammatory bowel disease, the pharmaceutical composition comprising vitamin C and the Bifidobacterium adolescentis AF91-08b2A according to claim 1, the mass ratio of the Bifidobacterium adolescentis AF91-08b2A to the vitamin C is 1:0.5, the amount of live bacteria of the Bifidobacterium adolescentis AF91-08b2A is (1~10000)×10 6 cfu / g.

[0017] A further technical solution of the present invention is: the pharmaceutical composition also includes one or more of milk growth factor, lactose, yeast powder or peptone, and the milk growth factor is obtained by mixing, centrifuging and ultrafiltering skim milk and casein; the mass ratio of the Bifidobacterium adolescentis AF91-08b2A, vitamin C, lactose, yeast powder and peptone is 1:0.5:2:2:1.

[0018] A further technical solution of the present invention is: the pharmaceutical composition also includes other functional bacteria, and the other functional bacteria are used to treat and / or prevent and / or alleviate inflammatory bowel disease.

[0019] A further technical solution of the present invention is that the pharmaceutical composition also includes milk powder, cyclodextrin, maltose, glucose, glycerol, sodium glutamate, mannose, galactose, mannitol or methylcellulose.

[0020] A further technical solution of the present invention is that the dosage form of the pharmaceutical composition is capsule, tablet, oral liquid, pill, granule or drop pill.

[0021] Another object of the present invention is to provide a food composition, the food composition comprising vitamin C and Bifidobacterium adolescentis AF91-08b2A, the mass ratio of Bifidobacterium adolescentis AF91-08b2A to vitamin C is 1:1, and the amount of live bacteria of Bifidobacterium adolescentis AF91-08b2A is (1~10000)×10 6 cfu / g.

[0022] A further technical solution of the present invention is: the food composition also includes milk and white sugar, and the mass ratio of the food composition, vitamin C, milk and white sugar is 0.5:0.5:90:9.

[0023] The present invention also provides an application of Bifidobacterium adolescentis AF91-08b2A in the preparation of a drug, wherein the drug is used to treat and / or prevent and / or alleviate inflammatory bowel disease. The Bifidobacterium adolescentis AF91-08b2A was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 13, 2024, with a deposit number of GDMCC NO: 64745.

[0024] Another object of the present invention is to provide an application of Bifidobacterium adolescentis AF91-08b2A in food / health products, wherein the food / health products are used to prevent inflammatory bowel disease, and the Bifidobacterium adolescentis AF91-08b2A was deposited in Guangdong Provincial Microbiological Culture Collection Center on June 13, 2024, with a deposit number of GDMCC NO: 64745.

[0025] Another object of the present invention is to provide a use of Bifidobacterium adolescentis AF91-08b2A, wherein the Bifidobacterium adolescentis AF91-08b2A is used to treat and / or prevent and / or alleviate inflammatory bowel disease, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

[0026] The beneficial effects of the present invention are: the strain can significantly improve the disease activity index (DAI) of DSS-induced UC mice, control the weight loss and colon shortening of UC mice, and improve the intestinal barrier function and reduce the inflammatory response. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1It is a schematic diagram of the genome circular map information of strain AF91-08b2A provided in an embodiment of the present invention.

[0028] Figure 2 It is a schematic diagram of the KEGG metabolic pathway annotation provided by an embodiment of the present invention.

[0029] Figure 3 It is a schematic diagram of the annotation of the beneficial metabolic pathway of strain AF91-08b2A provided in the embodiment of the present invention.

[0030] Figure 4 It is a schematic diagram of weight monitoring results provided by an embodiment of the present invention.

[0031] Figure 5 It is a schematic diagram of DAI scoring of the AF91 group provided in an embodiment of the present invention.

[0032] Figure 6 It is a schematic diagram of an image of colon tissue length provided by an embodiment of the present invention.

[0033] Figure 7 It is a schematic diagram of the statistical analysis of colon length provided in an embodiment of the present invention.

[0034] Figure 8 It is a representative micrograph of H&E staining of four groups of mouse colon tissues provided in the examples of the present invention.

[0035] Fig. 9 Schematic diagram of histopathological scoring provided by an embodiment of the present invention.

[0036] Fig.10 It is a schematic diagram of the effect of AF-91 provided in the examples of the present invention on the expression of pro-inflammatory and anti-inflammatory cytokines.

[0037] Fig.11 It is a schematic diagram of the effect of AF-91 provided in the examples of the present invention on intestinal tight junction proteins. DETAILED DESCRIPTION

[0038] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.

[0039] like Figure 1 As shown, the present invention provides Bifidobacterium adolescentis AF91 and its application in alleviating ulcerative colitis; 2.1 Technical Problems to be Solved by the Invention The present invention aims to provide a new probiotic for treating colitis, namely, application of Bifidobacteriumadolescentis AF91-08b2A. It has been proved that the strain can significantly improve the disease activity index (DAI) of DSS-induced UC mice, control the weight loss and colon shortening of UC mice, improve the intestinal barrier function and reduce the inflammatory response.

[0040] 2.2 Technical solution of the present invention In order to achieve the above object, the present invention adopts the following technical solutions: The present invention relates to a Bifidobacterium adolescentis AF91-08b2A, which is isolated from a healthy human body and shows a potential therapeutic effect on colitis.

[0041] The Bifidobacterium adolescentis AF91-08b2A described in the present invention is isolated using PYG culture medium, and the separation conditions are anaerobic conditions at 37°C.

[0042] The Bifidobacterium adolescentis AF91-08b2A selected in the present invention has been found to have a significant alleviating effect on colitis. Specifically, it can significantly improve the apparent state of mice with ulcerative colitis, reduce the disease activity index of mice, and relieve intestinal inflammation by repairing the intestinal barrier and regulating cytokine levels.

[0043] 2.3 Beneficial effects of the technical solution of the present invention The beneficial effects of the present invention are: Bifidobacterium adolescentis AF91-08b2A can effectively control the weight loss of DSS-induced UC mice, inhibit the increase of the disease activity index (DAI) of mice, improve the changes in the colon of mice, and relieve intestinal inflammation by repairing the intestinal barrier and regulating cytokine levels.

[0044] Example 1 Isolation and identification of Bifidobacterium adolescentis AF91-08b2A 1. Sample Collection Fecal samples were collected from healthy adults and transferred aseptically into sample tubes and brought back to the laboratory for processing within 1 hour.

[0045] 2. Isolation and purification of Bifidobacterium 0.2 g of fecal sample was mixed in 1 ml of sterile PBS, spread on the culture medium after gradient dilution, cultured under anaerobic conditions at 37°C, and single colonies were selected for isolation.

[0046] 3. Strain preservation The purified strain was cultured to a concentration of about 1×109 cfu / ml, and after adding 20% ​​glycerol, it was stored at -80°C for a long term.

[0047] Genomic DNA extraction and 16S rDNA identification After the isolated strain was cultured in liquid PYG medium for 24 hours, 1 ml of bacterial solution was taken and centrifuged at 10,000 rpm for 5 minutes to collect the bacteria. Subsequently, genomic DNA was extracted from the bacteria. Using genomic DNA as a template, PCR amplification was performed using the universal primer pair of 16S rDNA: forward primer (Forward Primer): 5'-AGAGTTTGATGGCTCAG-3' (SEQ ID NO: 1), reverse primer (Reverse Primer): 5'-TAGGGTTACCTTGTTACGACTT-3' (SEQ ID NO: 2). The PCR reaction system included: 3 μl of 10× PCR buffer, 2.5 μl of dNTP, 0.5 μl of forward primer, 0.5 μl of reverse primer, 0.3 μl of Taq DNA polymerase, 1 μl of template DNA, and deionized water to a total volume of 20 μl. The PCR amplification program was: 95°C pre-denaturation for 4 minutes, 95°C denaturation for 30 seconds, 57°C annealing for 40 seconds, and 72°C extension for 1 minute and 30 seconds, for a total of 30 cycles. After amplification, the 16S rDNA PCR product was detected and purified by gel electrophoresis and sequenced using a 3730 sequencer to obtain the 16S rDNA sequence (see SEQ ID NO: 3). The sequencing results were compared with the sequences in the GenBank database and the identification result was Bifidobacterium adolescentis AF91-08b2A.

[0048] SEQ ID NO: 3 Example 2 Analysis of genomic characteristics of Bifidobacterium adolescentis AF91-08b2A 1. Whole genome sequencing and assembly like Figure 1-3 As shown, the whole genome of Bifidobacterium adolescentis AF91-08b2A was sequenced using high-throughput sequencing technology, and 37 sequences were obtained with a total length of 2,242,707 bp.

[0049] 2. Genome Annotation The GTDB-Tk tool was used for genome classification, and 1803 coding DNA sequences (CDS) were predicted, including 4 rRNA genes, 53 tRNA genes and 1 tmRNA gene.

[0050] 3. Metabolic pathway analysis Metabolic pathway annotation was performed using eggNOG-mapper and the KEGG database, and it was found that the strain had strong metabolic functions and environmental adaptability.

[0051] Example 3 Safety evaluation of Bifidobacterium adolescentis AF91-08b2A 1. Antibiotic resistance gene detection The RGI tool and CARD database were used to predict antibiotic resistance genes, and genes such as rpoB mutant, tet(W), dfrF and ErmX were discovered.

[0052] Genes associated with antibiotic resistance 2. Virulence factor gene detection The VFDB database was used to predict virulence factor genes, and genes related to bacterial adhesion, immune regulation, anti-phagocytosis, and nutritional / metabolic factors were discovered.

[0053] Virulence factor genes Example 4 Study on the treatment of colitis mouse model with Bifidobacterium adolescentis AF91-08b2A 1. Animal Model Establishment C57BL / 6J male mice, 7 weeks old, that met the specific pathogen-free (SPF) standard were selected. They were adapted for one week in an SPF-grade laboratory environment and then randomly assigned to four different experimental groups. The groups were as follows: normal control group, dextran sulfate sodium (DSS) treatment group, 5-aminosalicylic acid (5-ASA) treatment group, and AF91 treatment group (see Table 1 for details of the groups).

[0054] From day 1 to day 14 of the experiment, mice in the AF91-treated group received daily intragastric administration of 1×10^9 CFU of bacterial solution, while mice in the 5-ASA-treated group received daily intragastric administration of 200 mg / kg body weight of 5-ASA. At the same time, mice in the DSS-treated group and the normal control group received an equal amount of phosphate buffered saline (PBS) by intragastric administration. From day 8 to day 14 of the experiment, 2.5% DSS was added to the drinking water of mice in all groups except the normal control group to induce colitis. The experimental design is shown in Table 1.

[0055] Table 1 Experimental design of mice 2. Observation and detection indicators and treatment: ① During the experiment, the weight of each mouse was monitored as the basis for the disease activity index (DAI) score. The specific operation is: the weight of the mice was measured at a fixed time point every day, and the excrement of the mice was observed and recorded. By comparing the current weight of the mouse with its initial weight, the percentage of weight change was calculated to assess the disease activity of the mouse. The DAI score consists of three indicators: weight loss, occurrence of diarrhea, and appearance of blood in the stool. The maximum score for each indicator is 4 points, and the total score is 12 points. The final DAI score is the average of the scores of these three indicators.

[0056] Table 2. DAI scoring criteria Note: DAI = (weight loss score + stool characteristics score + blood in stool score) / 3; the comprehensive score of DAI is between 0 and 4, with 0 representing normal and 4 representing the highest inflammatory activity.

[0057] ②On the 15th day of the experiment, the mice were weighed, blood was collected from their eyes after anesthesia, and the mice were killed by cervical dislocation. Subsequently, the collected blood samples were centrifuged to separate the serum and stored at -80°C for subsequent biochemical index testing. The length of the mouse colon was measured, and samples were taken for tissue sections. Some colon samples were used to make pathological sections for histological analysis under a microscope. The remaining colon tissue was frozen and stored at -80°C for future experimental studies.

[0058] ③ For samples of the distal colon (approximately 2 cm from the anus), they were first fixed with 4% paraformaldehyde, then dehydrated with ethanol and embedded in paraffin to make 5-micron cross-sectional slices. After dewaxing, the slices were stained with hematoxylin and eosin (H&E). The stained slices were observed under an optical microscope to evaluate the morphological characteristics of the colon tissue. Referring to the scoring criteria in Table 3, the degree of damage to the colon tissue was quantitatively scored according to the degree of infiltration of inflammatory cells, tissue damage, and epithelial cell damage.

[0059] Table 3. Pathological histological scoring criteria 3. Results: Disease Activity Index (DAI) score, weight change, and colon length In the study of colitis mouse model, we first monitored the weight changes and disease activity index (DAI) of mice. The DAI score combines weight loss, diarrhea and blood in stool to assess the degree of disease activity in mice. The results showed that compared with the DSS-treated group, the mice in the AF91-treated group showed significant improvements in weight loss and DAI scores, indicating that AF91 has a certain therapeutic effect on the colitis mouse model. The chart is shown in Figure 4 and Figure 5 The colon length of mice in the AF91-treated group was longer than that in the DSS group, indicating that AF91 has a certain positive effect on colon length and helps to improve colitis symptoms. The graph is shown in Figure 6 and Figure 7 middle.

[0060] 4. Histopathological evaluation results Furthermore, we performed pathological evaluation on the colon tissues of mice. H&E staining showed that the colon tissues of mice in the AF91-treated group showed less inflammatory cell infiltration and tissue damage, and the injury score was lower than that in the 5-ASA-treated group. Figure 8 and Fig. 9 middle.

[0061] Example 5 Bifidobacterium adolescentis AF91-08b2A regulates cytokine levels in a colitis mouse model ELISA was used to measure the levels of inflammatory factors (IFN-γ and IL-17A) and anti-inflammatory factors (IL-4 and TGF-β1) in colon tissues; qRT-PCR technology was used to measure the levels of inflammatory factors (IL-6, IL-1β and TNF-α) and anti-inflammatory factors (IL-10) in colon tissues. The application of ELISA and qRT-PCR techniques revealed the effect of the AF91 treatment group in reducing the levels of inflammatory factors (such as IFN-γ, IL-17A, IL-6, IL-1β and TNF-α) and increasing the levels of anti-inflammatory factors (such as IL-4, TGF-β1 and IL-10). These results indicate that AF91 may alleviate the symptoms of colitis by regulating the immune response. The results and figures are shown in Fig.10 shown.

[0062] Example 6 Bifidobacterium adolescentis AF91-08b2A improves intestinal barrier function in a colitis mouse model The mRNA expression levels of tight junction proteins (ZO-1, Occludin, and Claudin-2) were evaluated by qRT-PCR, and the expression of tight junction proteins (ZO-1, Occludin, and Claudin-2) was analyzed by western blot to evaluate the recovery of intestinal barrier function. We found that the expression levels of tight junction proteins in the colon tissue of mice in the AF91 treatment group were restored, indicating that AF91 may help repair intestinal barrier function. Related results and figures are shown in Fig.11 middle.

[0063] Example 7 Preparation of probiotics containing Bifidobacterium adolescentis AF91-08b2A 1. Probiotic culture Bifidobacterium adolescentis AF91-08b2A was cultured anaerobically in culture medium until the logarithmic growth phase.

[0064] 2. Microecological preparation formula Probiotics are mixed with protective agents, nutritional supplements, etc. to prepare a microecological preparation suitable for oral administration.

[0065] 3. Preparation stability test The prepared microecological preparations are subjected to stability tests to ensure the activity of probiotics during storage and use.

[0066] Example 8 Preparation of a pharmaceutical composition containing Bifidobacterium adolescentis AF91-08b2A Raw material ratio (mass percentage): Ensure that all raw materials are weighed and handled under sterile conditions. Cultivate the Bifidobacterium adolescentis AF91-08b2A strain in a suitable medium until the logarithmic growth phase. Mix lactose, yeast powder, peptone and vitamin C with purified water in the above proportions to ensure full dissolution and uniform distribution. Preheat the mixed raw materials at 60-65°C and homogenize them using a high-pressure homogenizer to ensure that the mixture is uniform and free of particles. Sterilize the homogenized mixture at around 90°C for 20-30 minutes to ensure that any harmful microorganisms that may be present are killed while maintaining the nutritional value and flavor of the product. Rapidly cool the sterilized mixture to 36-38°C in preparation for inoculation with probiotics. Inoculate the cooled mixture with a bacterial solution of Bifidobacterium adolescentis AF91-08b2A with a viable bacterial count of 1-500×10^6 cfu / mL. Ensure that the bacterial solution is evenly distributed. Ferment at 37°C until the pH value is 6.0. After fermentation is completed, the mixture is centrifuged to collect the cells. The collected cells are freeze-dried until the moisture content is less than 3% to obtain a freeze-dried product of Bifidobacterium adolescentis AF91-08b2A. 0.5 g of the freeze-dried product of Bifidobacterium adolescentis AF91-08b2A is weighed and mixed with an equal amount of maltodextrin and then filled into a capsule to prepare a pharmaceutical composition containing Bifidobacterium adolescentis AF91-08b2A.

[0067] Through the above steps, a pharmaceutical composition containing Bifidobacterium adolescentis AF91-08b2A can be prepared. This product not only has potential health benefits but also provides consumers with a convenient dosage form.

[0068] Example 9 Preparation of food compositions containing Bifidobacterium adolescentis AF91-08b2A Raw material ratio (mass percentage): According to the above ratio, mix milk, sugar and vitamin C and stir until completely mixed. Preheat the mixture to 60-65℃ and use 20Mpa pressure homogenization to ensure that the mixture is uniform. Sterilize the homogenized mixture at about 90℃ for 5-10 minutes to ensure that the mixture reaches commercial sterility standards. Cool the sterilized mixture to 40-43℃. Mix in the protective agent vitamin C and inoculate 1-100×10^6 cfu / g of Bifidobacterium adolescentis AF91-08b2A bacterial solution. Ferment at 37℃ until the pH value is 6.0. The fermented mixture is packaged. Aseptic packaging technology can be used to ensure the stability and safety of the product. The packaged product is stored under refrigerated conditions at 2-8℃ to maintain the activity of the probiotics and extend the shelf life.

[0069] The food composition contains Bifidobacterium adolescentis AF91-08b2A and has potential health benefits such as improving intestinal health and enhancing immunity. The homogeneity and safety of the product are ensured by homogenization and sterilization. It is suitable as part of the daily diet and helps to provide a probiotic supplement.

[0070] Changes in weight The results of weight monitoring are as follows Figure 4 As shown by Figure 4 It can be seen that the initial body weight (0d) and the body weight after 14d of intervention were monitored, and the body weight change rate was calculated. The specific results are shown in Figure 4. It can be seen that DSS-induced inflammatory bowel disease mice will lose weight. After continuous gavage of AF91 bacterial solution for 14 days, the AF91 group can significantly improve the weight loss of DSS mice compared with the model group (P<0.05); compared with the 5-ASA group, AF91 improved the weight loss of mice better than the 5-ASA group. The results show that AF91 bacterial solution can effectively reduce the weight loss symptoms caused by inflammatory bowel disease.

[0071] DAI Rating The DAI scores of the AF91 group were recorded and on day 14, there was a significant improvement in the AF91 group compared with the DSS group (P < 0.0001).

[0072] Image of colon tissue length Depend on Figure 6 It can be seen that AF91 bacterial liquid can significantly improve the colon shortening of DSS-treated mice.

[0073] Statistical analysis of colon length Figure 7The colon length of the DSS group (5.79 ± 0.46 cm) was significantly shorter than that of the control group (8.45 ± 0.52 cm) (P < 0.0001). The colon length of the AF91 group (7.15 ± 0.86 cm) was significantly longer than that of the DSS group (P < 0.05), indicating that AF91 may reduce the shortening of the colon in mice with DSS-induced colitis.

[0074] Figure 8 Representative micrographs of H&E-stained colon tissues from four groups of mice. Fig. 9 Scored for histopathology.

[0075] The results of colon histopathological analysis were as follows Fig. 9 As shown in the figure, the intestinal mucosal epithelial cells in the control group were intact and regular, without necrosis or shedding, and without inflammatory cell infiltration. In contrast, DSS caused intestinal submucosal edema, crypt damage, and inflammatory cell infiltration. From these results, we can speculate that AF91 can alleviate DSS-induced intestinal tissue damage, and the effect is better than that of the 5-ASA group.

[0076] like Fig.10 The effects of AF-91 on the expression of pro-inflammatory and anti-inflammatory cytokines are shown in Figure 2. (AD) ELISA was used to detect the levels of IL-4 (A), IL-17a (B), TGF-β1 (C), and IFN-γ (D) in colon tissues. (EH) Relative expression levels of mRNA in IL-1β, IL-6, IL-10, and TNF-α.

[0077] The number of cytokines in colon tissue can reflect the severity of inflammatory cell infiltration caused by DSS. Compared with the control group, the levels of IL-6, IL-1β and TNF-α in the colon tissue of the DSS group were higher than those of the control group (p<0.05) (Figure EI), and the level of IL-10 was lower than that of the control group (p<0.05). These effects were significantly improved after intervention with 5-ASA and AF91. To further evaluate the colon damage, we quantitatively analyzed the anti-inflammatory cytokines IL-4 and TGF-β1, as well as the pro-inflammatory cytokines IFN-γ and IL-17A in the colon tissue. The results showed that compared with the DSS group, the anti-inflammatory cytokines IL-4 and TGF-β1 in the AF91 and 5-ASA groups were significantly increased, as shown in Figure 5. Fig.10 As shown in A and C, the pro-inflammatory cytokines IFN-γ and IL-17A were significantly decreased. Fig.10 As shown in B and D. These results indicate that AF91 alleviates intestinal inflammatory responses in DSS-induced colitis mice by reducing the levels of pro-inflammatory factors and promoting the expression of anti-inflammatory factors.

[0078] like Fig.11Shown are the effects of AF-91 on intestinal tight junction proteins. Relative mRNA expression levels of ZO-1 (A), occludin (B), and claudin-2 (C); relative protein expression levels of ZO-1 (D), occludin (E), and claudin-2 (F).

[0079] Compared with the control group, the relative protein expression of ZO-1, occludin, and claudin-2 in the DSS group was significantly reduced, and the addition of AF91 partially restored the DSS-induced low protein expression (Figures DE). In addition, DSS reduced the gene transcription levels of ZO-1, occludin, and claudin-2 (Figures AC), which could be partially restored by supplementing AF91. These results suggest that AF91 treatment can reduce inflammatory responses by restoring the integrity of the intestinal barrier.

[0080] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Bifidobacterium adolescentis AF91-08b2A, characterized in that It was deposited in Guangdong Provincial Microbiological Culture Collection Center on June 13, 2024, and its deposit number is GDMCC NO:64745.

2. A pharmaceutical composition for treating and / or preventing and / or alleviating inflammatory bowel disease, characterized in that: The pharmaceutical composition comprises vitamin C and the adolescent bifidobacterium AF91-08b2A according to claim 1, wherein the mass ratio of the adolescent bifidobacterium AF91-08b2A to the vitamin C is 1:0.5, and the amount of live bacteria of the adolescent bifidobacterium AF91-08b2A is (1 to 10000)×10 6 cfu / g.

3. The pharmaceutical composition according to claim 2, characterized in that The pharmaceutical composition also includes one or more of milk growth factor, lactose, yeast powder or peptone, wherein the milk growth factor is obtained by mixing, centrifuging and ultrafiltering skimmed milk and casein; the mass ratio of the Bifidobacterium adolescentis AF91-08b2A, vitamin C, lactose, yeast powder and peptone is 1:0.5:2:2:

1.

4. The pharmaceutical composition according to claim 3, characterized in that The pharmaceutical composition also includes other functional bacteria, and the other functional bacteria are used to treat and / or prevent and / or alleviate inflammatory bowel disease.

5. The pharmaceutical composition according to any one of claims 2 to 4, characterized in that The dosage form of the pharmaceutical composition is capsule, tablet, oral liquid, pill, granule or dripping pill.

6. A food composition, characterized in that The food composition comprises vitamin C and the adolescent bifidobacterium AF91-08b2A according to claim 1, wherein the mass ratio of the adolescent bifidobacterium AF91-08b2A to vitamin C is 1:1, and the amount of live bacteria of the adolescent bifidobacterium AF91-08b2A is (1 to 10000)×10 6 cfu / g.

7. The food composition according to claim 6, characterized in that The food composition also includes milk and white sugar, and the mass ratio of the food composition, vitamin C, milk and white sugar is 0.5:0.5:90:

9.

8. Use of Bifidobacterium adolescentis AF91-08b2A in the preparation of medicines, characterized in that: The drug is used to treat and / or prevent and / or alleviate inflammatory bowel disease. The Bifidobacterium adolescentis AF91-08b2A was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 13, 2024, and its preservation number is GDMCCNO:64745.

9. Application of Bifidobacterium adolescentis AF91-08b2A in food / health products, characterized in that: The food / health product is used to prevent inflammatory bowel disease. The Bifidobacterium adolescentis AF91-08b2A was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 13, 2024, and its preservation number is GDMCC NO:64745.

10. Use of Bifidobacterium adolescentis AF91-08b2A, characterized in that: The Bifidobacterium adolescentis AF91-08b2A is used for treating and / or preventing and / or alleviating inflammatory bowel disease, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Citation Information

Cited By

  • Brawler's bacteria EMF75-02B1B and application thereof

    CN119709558A

  • Solid beverage and dairy product based on bifidobacterium adolescentis AF91-08b2A and application of solid beverage and dairy product

    CN120436328A

  • Bacterial strain for preventing and / or treating ulcerative colitis, mixed probiotics and application of bacterial strain and mixed probiotics

    CN120624307A